Biomedicine Daily · Sunday, 4 October 2026
CBA FRONTIER INSIGHTS
Weekly Oral Islatravir-Lenacapavir Matches Daily HIV Regimen in Phase 3
A phase 3 trial in 607 adults with virologically suppressed HIV-1, published in the New England Journal of Medicine, found that a once-weekly oral combination of islatravir and lenacapavir maintained viral suppression as effectively as once-daily bictegravir-emtricitabine-tenofovir alafenamide. At week 48, no participant on ISL/LEN had HIV-1 RNA of 50 copies per milliliter or higher, compared with 1 participant (0.3%) on B/F/TAF, meeting the 4-percentage-point noninferiority margin. The result gives suppressed patients a long-acting weekly oral option instead of a daily three-drug pill. The day also brought major licensing news, including Dizhe Pharmaceutical's grant of worldwide rights to AstraZeneca for $600 million upfront and InnoCare's discovery and license deal with Eli Lilly worth up to $3.35 billion.
Clinical readouts and safety
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Once-weekly oral islatravir-lenacapavir maintained viral suppression as well as once-daily bictegravir-emtricitabine-tenofovir alafenamide in a phase 3 trial of 607 adults with virologically suppressed HIV-1. At week 48, HIV-1 RNA of 50 copies per milliliter or higher was reported in no ISL/LEN participants and 1 (0.3%) on B/F/TAF, meeting a 4-percentage-point noninferiority margin. The finding supports a long-acting weekly oral option for suppressed patients.
TAVI-First Strategy Noninferior to PCI-First in Severe Aortic Stenosis with Coronary Disease
In severe aortic stenosis with coronary artery disease, performing TAVI before PCI was noninferior to PCI first for the one-year primary composite endpoint after randomization, the randomized TAVI PCI trial in NEJM shows; superiority was not established. All-cause death was 9.5% in both groups, and the TAVI-first group had lower rates of BARC type 3a bleeding. The trial, run across 29 high-volume German heart valve centers, is the first randomized comparison of the two staging orders when both procedures are planned.
medicalxpress.comNew weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells
CBL-514, an injectable that selectively induces apoptosis of fat cells, cut abdominal visceral adipose tissue volume by 12.01% from baseline four weeks after the last treatment in phase 2 participants (n=23), while placebo recipients (n=17) gained 5.68%, a 17.69 percentage-point difference. At later follow-up the between-group difference was 22.21 percentage points, and the drug was generally well tolerated with mostly mild injection-site reactions. Phase 3 trials for nonsurgical abdominal fat reduction are now recruiting.
Regulatory and policy
Industry and deals
Dizhe Pharmaceutical Grants AstraZeneca Worldwide Rights to Its Drug Shuwozhe for $600 Million Upfront
Dizhe Pharmaceutical granted AstraZeneca exclusive worldwide rights to develop and commercialize its drug Shuwozhe under a license agreement signed on July 13, 2026. Dizhe receives a one-time, non-refundable $600 million upfront payment, up to $400 million in clinical development milestone payments, up to $500 million in sales milestone payments, plus tiered royalties on global sales at rates rising to the low double digits.
InnoCare Signs Up to $3.35 Billion Discovery and License Deal with Eli Lilly
InnoCare's wholly owned subsidiary Beijing InnoCare Pharmaceutical Technology has signed a research collaboration and license agreement with Eli Lilly and Company. InnoCare will use its proprietary drug discovery platform to discover and develop up to five novel target programs. Lilly will pay up to $100 million upfront and in near-term milestones, plus about $3.25 billion in potential development and commercialization milestone payments.
biocentury.comCircle’s $92.5M round puts cyclin D1 program ahead of clinical lead
Circle Pharma raised a $92.5 million series E, announced Sept. 16, to advance preclinical cyclin D1 inhibitor CID-165 toward a planned clinical start in early 2027, making it the company's top priority over cyclin A/B inhibitor CID-078, which continues in Phase I. CEO David Earp said preclinical combination data drove the decision, with the aim of producing deeper responses in ER-positive breast cancer.
news.google.comAbbott launches SimpleScreen CRC blood test in the US - Fierce Biotech
Varda Space Industries Raises $251 Million Series D to Scale Orbital Drug Manufacturing
Varda Space Industries, founded in 2021 in El Segundo and led by CEO Will Bruey, closed a $251 million Series D round on 30 September 2026, lifting total funding to $598 million, with Lux Capital and Natural Capital leading and Founders Fund among the investors. The company operates as an orbital microgravity CDMO/CRO rather than a launch provider, and has completed six Falcon 9 rideshare missions, the first crystallizing the antiviral drug Ritonavir in orbit before landing at the Utah test range. Two more orbital modules, W-8 and W-9, are set to fly on Falcon 9's Transporter-18 rideshare in early October.
Research papers
Chemotherapy enhances cancer vaccine efficacy and expands stem-like TCF1+CD8+ T cells.
Carboplatin plus paclitaxel (CarboTaxol) and cyclophosphamide act as immunological adjuvants that improve the efficacy of heterologous prime-boost viral vector vaccines and enhance antigen-specific CD8+ T cell responses, independently of tumor presence. CarboTaxol drives early, antigen-independent expansion of stem-like TCF1+CD8+ T cells, seen also in patients with different cancer types, and disrupting TCF1 abolishes this adjuvant effect. Adding PD-1 blockade further improves tumor control and survival, supporting clinical testing of the triple combination.
medicalxpress.comAn epigenetic blueprint reveals how aggressive MYC amplification fuels cancer
MYC gene copy-number amplification is a biologically regulated process, not a random mutation event, controlled by chromatin proteins KDM4C and SETD2. When SETD2 is lost, KDM4C accesses the MYC region and recruits DNA-copying machinery to produce extra MYC copies, which progress to extrachromosomal DNA and tumors when TP53-dependent cell death fails. Blocking KDM4C, including with a clinically used KDM4 inhibitor, reduced MYC amplification in cells and animal models.
medicalxpress.comInflammation can reactivate 'sleeping' cancer cells hidden in the bone
Inflammation in the gut can wake dormant metastatic breast cancer cells in bone, according to work in Cell Reports using a new extramedullary bone model grown from skeletal stem cells in mice. Distant colitis drove immune cell production in the bone, and the growth-stimulating molecule HMGB2 rose and promoted reactivation of the sleeping cells; HMGB2 alone sufficed, and appeared alongside dividing cancer cells in human bone samples from people with breast or prostate cancer. The finding points to monitoring infections, inflammation or injury after remission as a marker of relapse risk.
doi.orgSpatial multi‑omics identifies an SPP1+ macrophage‑driven anti‑apoptotic niche in osteoarthritis synovium via the SPP1‑CD44 axis
Spatial multi-omics of osteoarthritis synovium identifies a TGF-β-enriched niche where SPP1+ macrophages expand next to senescent synovial fibroblasts and suppress apoptosis of inflammatory macrophages via the SPP1-CD44 axis, while recruiting myeloid cells through CCL3. In a mouse OA model, adeno-associated virus-mediated SPP1 knockdown or CCL3 neutralization restored macrophage apoptosis and attenuated synovitis and cartilage degeneration. SPP1+ macrophages thus act as pro-inflammatory rather than only pro-fibrotic cells.
medicalxpress.comHidden lymphatic signal amplifier could inform treatments for lymphedema and cancer metastasis
A KAIST and IBS team determined the cryo-EM structure of the VEGF-C-VEGFR-3 complex and found that complexes, each containing two VEGFR-3 receptors, assemble side by side into higher-order clusters that amplify lymphangiogenic signaling. Mutations disrupting this cis-cluster formation markedly reduced activation of VEGFR-3 and ERK despite VEGF-C stimulation. The clustering step identifies a new point at which lymphangiogenic signaling could be enhanced in lymphedema or suppressed in cancer metastasis.
Convergent evolution of metabolic regulation governs redox adaptation in Toxoplasma.
A screen in Toxoplasma gondii for genes supporting fitness at high parasite density identified NAD(P)+ biosynthesis and a parasite-specific RNA-binding protein, TgPRO. Loss of TgPRO raised reactive oxygen species under ambient conditions, an effect rescued by low oxygen growth, and TgPRO controlled transcripts for carbon metabolism and iron-sulfur cluster assembly, binding the ISCU transcript's 3' UTR. TgPRO is the first dedicated regulator of metabolic gene expression known in apicomplexans, evolved convergently to resemble metabolic regulators of other species.
medicalxpress.comResearchers report early results from therapy designed for a single patient with a rare genetic form of ALS
A bespoke antisense oligonucleotide targeting a CHCHD10 mutation lowered neurofilament light, a blood biomarker of nerve-cell injury, by as much as 50% in a single patient with a rare genetic form of ALS. Over the first six doses, delivered into spinal fluid, treatment was well tolerated and measures of breathing, cognition and physical function stayed stable or modestly improved. It shows an N-of-1 genetically targeted therapy can be developed and tested for an ultrarare disease.
medicalxpress.comGeneric, brand-name multiple sclerosis drugs may produce varied effects
Generic formulations of dimethyl fumarate, fingolimod and teriflunomide were linked to less consistent biomarker profiles than brand-name versions in multiple sclerosis patients. Analysis of serum biomarker data from 1,124 patients showed greater variability in immune-related blood proteins tied to MS disease activity among those taking generics, published in Clinical Immunology. The study did not evaluate clinical outcomes such as relapse rates or disability progression.
Methods and resources
medicalxpress.comRNA urine test outperforms standard bladder cancer tests and could help guide treatment
A urine RNA test called uRARE-seq identified 95% of people with localized bladder cancer and correctly classified 90% of those without it, outperforming standard urine cytology and a DNA-based urine test in a study of 683 urine samples. The test detects cell-free RNA fragments rather than DNA mutations, tracks tumor biology including low- versus high-grade disease, and identified residual disease after surgery and BCG immunotherapy. A derived biomarker predicted whether tumors were more likely to respond to immunotherapy or chemotherapy.
State method predicts cell perturbation responses across contexts without large-scale experiments
A Cell paper proposes a method called State for predicting how cells respond to perturbations across different cellular contexts, without requiring large-scale single-cell perturbation experiments. Current approaches such as single-cell CRISPR screening or small-molecule perturbation deliver transcriptome-level readouts in a given context, but their high cost limits scaling across contexts, and existing deep learning models often fail to outperform simple linear models when generalizing perturbation effects across contexts.
news.mit.eduAI-Optimized LNP Formulation Keeps RNA Vaccines Stable for a Year at Room Temperature
MIT researchers used an AI algorithm to optimize lipid nanoparticle excipient ratios, producing an RNA vaccine formulation stable for one year at room temperature or two months at 37 degrees Celsius. In mouse experiments it elicited immune responses similar to Moderna's vaccine. The algorithm converged on the optimal formulation with little experimental data, cutting a screening process that took months down to weeks. The work appears in Nature Biotechnology.
arxiv.orgPHASE: A Physiology-Guided Hierarchical Foundation Model for Intracranial EEG
PHASE, a physiology-guided foundation model for intracranial EEG, uses measurable physiological characteristics as explicit learning targets alongside masked latent prediction, pretrained on recordings from 222 participants at nine clinical sites. On all five Omni-iEEG clinical tasks, frozen PHASE-T beats every evaluated foundation model by up to 31%, and fine-tuned PHASE-T surpasses task-specific models. Ablations show physiological supervision drives the gains, and PHASE-ST further improves seizure-onset-zone identification.
medicalxpress.comMass spectrometry offers faster look at the edges of brain tumors
Syringe touch spray mass spectrometry can distinguish glioma from nontumor brain tissue in roughly three minutes, using ratios of endogenous metabolites measured from samples on a hypodermic needle plunger. In 86 human brain samples taken during MRI-guided surgery, the method separated diseased from healthy tissue with high confidence and also classified tumor subtypes and mutation status. It could give surgeons molecular margin information during operations, which standard pathology provides only afterward.
arxiv.orgGenerative modeling of intrinsically disordered protein regions by reinforcing sparse autoencoder features
IDiom, an autoregressive protein language model trained on 54 million predicted intrinsically disordered protein regions curated from the AlphaFold Database, generates diverse sequences matching natural IDR composition, motifs, and predicted disorder. A post-training method, reinforcement learning with sparse autoencoder features (RL-SAE), steers generation toward specified feature sets: across eight IDR design tasks, RL-SAE sequences activate 90% of 30 targeted features on average, versus 24% for activation steering, and improve predicted subcellular localization and transcriptional activity. The approach enables interpretable, composable IDR design by explicit control of function-associated sequence features.
arxiv.orgA Generalisation Signal Need Not Be a Model-Selection Signal
A forward-only proxy motivated by the Hessian norm was tested against common Hessian measures for ranking models in molecular property, protein fitness, and drug-response tasks. The proxy correlated with generalisation gap on most tasks even when Hessian trace and top-eigenvalue relationships were weak or reversed, but it did not reliably identify the deployment-best model, and augmenting validation helped some distribution shifts while significantly harming others. The finding separates generalisation signals from model-selection signals, showing curvature-based scores need not preserve cross-model rankings.
Also today
16 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
RegulatoryFDA Approves Edwards Lifesciences' Size · Signal or noise? > Ultragenyx says EMA validates MPS IIIA application · Novo India3 ▾▴
Filings, acceptances, designations, approvals and withdrawals at a regulator.
- FDA Approves Edwards Lifesciences' SizeUpdateEdwards Lifesciences said on October 1, 2026 that the FDA has approved the AUTUS pulmonary valve, a size-adjustable valve designed for children with congenital heart disease that can expand as the child grows. Valve enlargement is done through minimally invasive transcatheter procedures, which may reduce the need for repeat open-chest surgeries that children traditionally face years after valve replacement.FDA
- Signal or noise? > Ultragenyx says EMA validates MPS IIIA applicationUpdateEMA
- Novo IndiaUpdate
Clinicalretatrutide · FHD-909（LY4050784） · A single · VYD2311 …6 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- retatrutideUpdateIn the TRIUMPH phase 3 trial of retatrutide, a GIP/GLP-1/glucagon triple agonist, 1,152 people with type 2 diabetes and obesity lost 12.7%, 19.1%, and 20.8% of body weight over 80 weeks on 4, 9, and 12 mg respectively, versus 4.0% on placebo. Discontinuation for adverse events was higher on 9 mg (11.6%) than on 12 mg (7.7%), and community discussion of the data questions whether the top dose is worth it. Lilly plans to file for approval in early 2027.
- FHD-909（LY4050784）UpdateFoghorn Therapeutics is laying off about 40% of its staff, leaving roughly 65 employees, after its collaboration with Eli Lilly collapsed. Per Foghorn's 8-K dated 2026-10-01, the partners decided not to advance the SMARCA2 inhibitor FHD-909 (LY4050784) into expansion cohorts after disappointing Phase 1 dose-escalation data, and also ended work on a selective SMARCA2 degrader programme. The cuts extend Foghorn's cash runway into the second half of 2029; its shares fell about 40–49% on the day.
- A singleUpdate
- VYD2311UpdateVYD2311, a monoclonal antibody against the novel coronavirus on the same backbone as the authorized Pemgarda and the investigational adintrevimab, met the primary safety endpoint in the phase 3 LIBERTY trial of 210 healthy adults aged 18 to 49 across three arms: VYD2311 alone, with an mRNA vaccine, or vaccine alone. Tolerability was better than the mRNA vaccine and VYD2311 did not interfere with vaccine neutralizing titers. The company plans to submit a BLA to the FDA under the accelerated approval pathway as a pre-exposure prophylaxis, with key efficacy data from DECLARATION expected in October 2026.FDA
- ALN-CIDEBUpdateRegeneron has started the first Phase III trial of ALN-CIDEB, an siRNA therapy targeting CIDEB developed with Alnylam. The randomized, double-blind, placebo-controlled trial will enroll 1500 adults with MASLD to evaluate efficacy and safety, aiming to suppress fat accumulation in liver cells for MASH and other liver diseases. Phase III entry moves this CIDEB-directed approach into late-stage testing.
- AdectoUpdate
Deals and financingNovartis Licenses Abogen's mRNA · Merck Licenses Sipurei KRAS G12D(ON) Inhibitor SPR2015 for $2.13 Billion and Files IND · Pharma partnering in China gets earlier and broader · Hatteras Venture Partners …6 ▾▴
Licensing, M&A and financing that did not make the daily.
- Novartis Licenses Abogen's mRNAUpdateNovartis has signed a license agreement with Abogen Bio for ABO2203, an mRNA-encoded CD19xCD3 T cell engager, paying $575 million up front with potential milestone payments of $7.2 billion. Novartis views ABO2203 as mechanistically differentiated from conventional recombinant TCEs, with potential to reshape autoimmune treatment. In vivo TCEs maintain steadier drug levels, avoiding sharp concentration peaks that drive cytokine release.
- Merck Licenses Sipurei KRAS G12D(ON) Inhibitor SPR2015 for $2.13 Billion and Files INDUpdateMerck has licensed SPR2015, a KRAS G12D(ON) inhibitor developed by Sipurei, paying $400 million upfront in a deal worth up to $2.13 billion; the transaction has closed. SPR2015 showed nanomolar-level, highly selective inhibitory activity and antitumor effects as a monotherapy in multiple CDX/PDX models, with preclinical data presented at the 2026 AACR meeting. An IND application for SPR2015 has now been filed.
- Pharma partnering in China gets earlier and broaderUpdate
- Hatteras Venture PartnersUpdate
- Teva, Samsung Bioepis deepen bonds in pact for up to 6 new biosimilarsUpdate
- Dupixent Nears Patent Expiry and Sanofi Searches for a SuccessorUpdateDupixent, the autoimmune drug from Sanofi and Regeneron with annual sales of about 17.8 billion, faces the final five years before patent expiry. The two companies are now working to find a successor product for Dupixent. The Chinese headline cites a deal value of 8 billion dollars.
OtherImpending changes to U.S. human subject protections put ethicists on edge.1 ▾▴
Everything else with a concrete event that did not make the daily.